Abstract: The present invention provides compositions and methods to treat lymphoma and cancer. In particular, the present invention provides treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. The present invention further provides compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies.

Abstract: Compositions and methods to treat lymphoma and cancer are disclosed. In particular, the method teaches treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. Further taught are compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies.

Abstract: Methods and compositions that determine the expression levels of Stat4? and Stat4? isoforms for therapeutic efficacy of anti-inflammatory treatments, assessing an individual's risk for developing inflammatory diseases including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and multiple sclerosis are disclosed.

Abstract: ELF3 gene compositions associated with cancer are provided, including ELF3 mRNA intron retention, a novel ELF3 5? untranslated region, and a novel Alu, Alukwd. Methods and kits using primers or probes to detect the presence of these ELF3 gene compositions are also provided. Methods for determining whether a cell comprises a virus are also provided.

Abstract: ELF3 gene compositions associated with cancer are provided, including ELF3 mRNA intron retention, a novel ELF3 5? untranslated region, and a novel Alu, Alukwd. Methods and kits using primers or probes to detect the presence of these ELF3 gene compositions are also provided. Methods for determining whether a cell comprises a virus are also provided.

Abstract: The present invention relates to compositions and methods for cancer diagnosis and therapy, including but not limited to, cancer markers. In particular, the present invention relates to HERV-K(HML-2) target titers as diagnostic markers, and HERV-K(HML-2) therapeutic targets for HIV-related cancers, and other cancers.

Abstract: The invention provides methods and compositions for evaluating modulators of the Stat6 signaling pathway; in a particular, transgenic mice comprising a transgene within a Stat6 allele locus, encoding a selectable marker and displacing the SH2-encoding domain of the Stat6 allele. More particularly, the transgene may comprise 3' and 5' regions with sufficient complementarity to the natural Stat6 allele at the locus to effect homologous recombination of the transgene with the Stat6 allele. Such mice provide useful animal models for determining the effect of candidate drugs on a host deficient in Stat6 function. The invention provides a variety of methods for making and using the subject compositions; in particular, methods for determining the effect of a candidate drug on a mouse deficient in Stat6 function and methods of evaluating the side effects of a Stat6 function inhibitor.